Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 16, 2016. The document serves as a transaction notification regarding insider trading activities involving a Person Discharging Managerial Responsibilities (PDMR) and a Person Closely Associated (PCA).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of a specific share transaction and does not contain financial performance data.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a single transaction event: the transfer of 17,849 Ordinary Shares (ISIN: GB0009252882) from Ms. E Walmsley (CEO Designate) to her spouse, Mr. D Owen, for nil consideration on December 15, 2016.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the mechanics of the share transfer notification.
Key Facts for Investor Verification
- Transaction Type: Transfer of Ordinary Shares for nil consideration.
- Parties Involved: Ms. E Walmsley (CEO Designate) and Mr. D Owen (PCA).
- Volume: 17,849 shares.
- Date: December 15, 2016.
- Price: £0.00 per share.